Bevacizumab with focused ultrasound for recurrent glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding a focused ultrasound system (NaviFUS) to the drug bevacizumab can help people whose glioblastoma has come back. The treatment aims to deliver the drug more precisely to the brain tumor and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your glioblastoma has come back after standard treatment (radiation and temozolomide).
- You have not had bevacizumab or similar anti-VEGF drugs before.
- You are not currently using tumor treating fields (TTF) therapy.
- You are not taking blood thinners (like warfarin or aspirin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called sonodynamic therapy that uses sound waves and a special drug to target brain tumors that have come back. It aims to see if this approach is safe and can shrink tumors in people who are eligible for surgery.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This trial tests a combination of focused ultrasound and the immunotherapy drug pembrolizumab for people whose glioblastoma has returned after standard treatment. The ultrasound may help the drug work better by temporarily opening the blood-brain barrier.
This trial tests whether focused ultrasound can safely open the blood-brain barrier to help your chemotherapy work better. It is for people with glioblastoma who have already completed standard surgery and chemo-radiation and are now on maintenance chemo.
This Phase 2 study tests a protective approach using bevacizumab (a medicine that blocks VEGF) while doctors carefully increase the dose in people with glioblastoma. It’s meant to help control tumor growth and possibly reduce certain risks that can happen with blood-vessel–targeting treatments.
This trial tests a new combination of two drugs, HF1K16 and bevacizumab, for people whose glioma has come back or grown after prior treatment. It aims to see if this combination can help when standard options are no longer working or tolerable.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.